MARLBOROUGH, Mass.–(BUSINESS WIRE) January 23, 2023 –TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. Brenzavvy is…Original Article
FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
